Charles Schwab’s Nuvectis Pharma NVCT Stock Holding History

Charles Schwab’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05M	Buy	57,133 +7,488	+15%	+$83.8K	﹤0.01%	2995
2026 Q1	$384K	Buy	49,645 +5,623	+13%	+$48.2K	﹤0.01%	3189
2025 Q4	$332K	Buy	44,022 +6,040	+16%	+$39.4K	﹤0.01%	3257
2025 Q3	$229K	Hold	37,982	–	–	﹤0.01%	3336
2025 Q2	$284K	Buy	+37,982	New	+$344K	﹤0.01%	3330
2024 Q2	–	Sell	-19,920	Closed	-$163K	–	3663
2024 Q1	$163K	Hold	19,920	–	–	﹤0.01%	3261
2023 Q4	$166K	Hold	19,920	–	–	﹤0.01%	3298
2023 Q3	$257K	Buy	19,920 +1,925	+11%	+$27.9K	﹤0.01%	3242
2023 Q2	$287K	Buy	+17,995	New	+$287K	﹤0.01%	3243

Other funds holding NVCT

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Charles Schwab's NVCT Position: Q2 2026 in Review

Charles Schwab increased its Nuvectis Pharma (NVCT) stake by 15% in Q2 2026, buying an estimated $83.8K and bringing the position to 57,133 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2995.

Charles Schwab first reported a position in NVCT in Q2 2023 and has held it in 9 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

Charles Schwab held 57,133 shares of Nuvectis Pharma worth $1.05M as of Q2 2026.
Charles Schwab bought 7,488 Nuvectis Pharma shares in Q2 2026, an estimated $83.8K.
Nuvectis Pharma made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2995 holding.
Charles Schwab first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 9 quarters since.
83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.